Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Voglibose: Difference between pages

{{Short description|Alpha-glucosidase inhibitor}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

| verifiedrevid = 470631324

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| C=10 | H=21 | N=1 | O=7

'''Voglibose''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]], trade name '''Voglib''', marketed by Mascot Health Series) is an [[alpha-glucosidase inhibitor]] used for lowering postprandial blood glucose levels in people with [[diabetes mellitus]].<ref name="pmid16457643">{{cite journal | vauthors = Chen X, Zheng Y, Shen Y | title = Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors | journal = Current Medicinal Chemistry | volume = 13 | issue = 1 | pages = 109–116 | date = 2006 | pmid = 16457643 | doi = 10.2174/092986706789803035 }}</ref> Voglibose is a research product of [[Takeda Pharmaceutical Company]], Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994,<ref name="NCBIDec72013">{{cite journal | vauthors = Dabhi AS, Bhatt NR, Shah MJ | title = Voglibose: an alpha glucosidase inhibitor | journal = Journal of Clinical and Diagnostic Research | volume = 7 | issue = 12 | pages = 3023–3027 | date = December 2013 | pmid = 24551718 | pmc = 3919386 | doi = 10.7860/JCDR/2013/6373.3838 }}</ref> under the trade name BASEN, to improve postprandial hyperglycemia in [[diabetes mellitus]].<ref>{{cite web | title = Voglibose | url = https://adisinsight.springer.com/drugs/800001172 | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref>

[[Postprandial]] [[hyperglycemia]] (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.<ref name="NCBIDec72013"/>

There are three major drugs which belong to this class, [[acarbose]], [[miglitol]] and voglibose,<ref name="NCBIDec72013"/> of which voglibose is the newest.

== Efficacy ==

A [[Cochrane (organisation)|Cochrane]] [[systematic review]] assessed the effect of alpha-glucosidase inhibitors in people with impaired [[Prediabetes|glucose tolerance]], impaired [[Glucose test|fasting blood glucose]], elevated glycated hemoglobin A1c ([[Glycated hemoglobin|HbA1c]]).<ref name=":0">{{cite journal | vauthors = Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA | title = Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | volume = 2018 | issue = 12 | pages = CD005061 | date = December 2018 | pmid = 30592787 | pmc = 6517235 | doi = 10.1002/14651858.CD005061.pub3 |collaboration = Cochrane Metabolic and Endocrine Disorders Group }}</ref> It was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved [[Mortality rate|all-cause mortality]], reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal [[stroke]], [[Heart failure|congestive heart failure]], or non-fatal [[myocardial infarction]].<ref name=":0" />

== References ==

{{Reflist}}

== Further reading ==

{{refbegin}}

* {{cite book | vauthors = Miller CK | chapter = New therapeutic options in the treatment of diabetes mellitus | veditors = Greenstein B | date = 2004 | title = Clinical Pharmacology for nurses | edition = 17th | publisher = Elsevier Limited, Churchill Livingstone }}

* {{cite book | vauthors = Wilson L |date = 1997| veditors = Mehra IV |publisher=[[Aspen Publishers]]|pages=62–63|title=Managing the Patient with Type II Diabetes |url= https://books.google.com/books?id=NiKUGHtQrvsC&dq=voglibose&pg=PA62 |isbn=978-0-8342-1018-9}}

{{refend}}

{{Oral hypoglycemics and insulin analogs}}

[[Category:Alpha-glucosidase inhibitors]]

[[Category:Amino sugars]]